Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746883 · ClinicalTrials.gov registry record
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
A clinical trial of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), sponsored by Innoviva Specialty Therapeutics.
- Recruiting
- Registry status
- 100
- Enrollment target
- 8
- Study locations
NCT06746883: Recruiting study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), sponsored by Innoviva Specialty Therapeutics.
NCT06746883 is a study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) that is actively recruiting participants, run by Innoviva Specialty Therapeutics. The registered enrollment target is 100 participants. The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06746883, a study of Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), is actively recruiting participants, sponsored by Innoviva Specialty Therapeutics.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.
Conditions Studied
Interventions
- OTHER Non-interventional
Study Locations (8)
Louisiana
- Ochsner Medical Center - New Orleans - New Orleans
- Ochsner LSU Health Science Center Shreveport - Shreveport
Ohio
- Summa Health System - Akron - 75 Arch Street - Akron
- The Carl and Edyth Lindner Center for Research and Education at Christ Hospital - Cincinnati
Kansas
- University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd - Kansas City
Kentucky
- University of Kentucky College of Medicine - Lexington
New York
- Montefiore Medical Group Family Care Center - The Bronx
South Carolina
- Prisma Health - Infectious Diseases - Greenville - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2029-01-31 |
What NCT06746883 shows while recruiting
NCT06746883 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) appearing as the primary indexed condition, and to 1 intervention - of which Non-interventional is the first listed.
NCT06746883 lists 8 locations in 6 states (Louisiana, Ohio, Kansas).
Frequently Asked Questions
What is clinical trial NCT06746883 about?
NCT06746883 is a clinical study titled "A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection". The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in ...
What is the current status of trial NCT06746883?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-28. Estimated completion is 2029-01-31.
What conditions does trial NCT06746883 study?
This clinical trial studies the following conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC).
What interventions are being tested in trial NCT06746883?
The interventions under investigation include: Non-interventional (OTHER).
Who is sponsoring clinical trial NCT06746883?
This trial is sponsored by Innoviva Specialty Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06746883 being conducted?
This trial has 8 study locations across Kansas, Kentucky, Louisiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI